Clinical Report: The CRISPR-powered Diagnostic SLEUTH
Overview
Researchers have developed a DNA-guided CRISPR–Cas12a system for RNA detection. The SLEUTH platform demonstrated high sensitivity and specificity in detecting RNA targets, including SARS-CoV-2.
Background
The development of rapid and accurate molecular diagnostics is crucial for effective disease management, particularly in infectious diseases. CRISPR technology has emerged as a powerful tool in this field, with traditional systems relying on RNA guides.
Data Highlights
| Parameter | Result |
|---|---|
| Analytical Sensitivity | Attomolar (1 aM) |
| Clinical Concordance with RT-qPCR | 100% on 31 SARS-CoV-2 samples |
Key Findings
- The DNA-guided Cas12a system can accurately recognize and cleave single-stranded RNA.
- It demonstrated trans-cleavage activity, producing detectable fluorescent signals.
- The assay could detect RNA targets at low concentrations without preamplification.
- It distinguished single-nucleotide sequence differences, aiding mutation detection.
- In HEK293T cells, it reduced EGFP mRNA expression with minimal off-target effects.
Clinical Implications
The DNA-guided CRISPR system may enhance the accuracy of RNA-targeted diagnostics and therapies. Its ability to function in living cells suggests potential applications in gene editing and precision medicine.
Conclusion
The study presents a promising advancement in CRISPR technology, with the potential to improve molecular diagnostics and RNA-targeting tools. Further optimization is needed to enhance the stability and efficacy of the DNA-guided system.
Related Resources & Content
- Nature Biotechnology, 2026 -- DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
- The Journal of Infectious Diseases — CRISPR-Cas–associated SCCmec Variants in Methicillin-resistant Staphylococcus aureus Evade Rapid Diagnostic Detection
- Journal of Medical Internet Research (JMIR) — CRISPR Diagnostics, in Your Pocket
- Clinical Rheumatology — Identifying Genetic Drug Targets in Systemic Lupus Erythematosus: Insights from a Genome-Wide Mendelian Randomization Analysis
- Clinical Rheumatology — Bioinformatics Integration and Clinical Validation Identify PRDX6 as a Key Mitochondrial Gene in Systemic Lupus Erythematosus
- Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV | Influenza (Flu) | CDC
- DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage | Nature Biotechnology
- Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV | Influenza (Flu) | CDC
- Development and clinical validation of an ERA-CRISPR/Cas12a assay for the rapid detection of 14 high-risk HPV types | Microbiology Spectrum
Based on findings from:
The CRISPR-powered Diagnostic SLEUTH
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/may/the-crisprpowered-diagnostic-sleuth/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
